Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
COVID-19(DisCoVeRy)로 입원한 환자의 치료를 위한 렘데시비르 + 표준 치료 대 표준 치료 단독: 3상, 무작위, 대조, 공개 시험
Clinical Trial
[키워드] Abstract
activities
activity
acute respiratory distress
acute respiratory distress syndrome
adaptive
Administered
Adult patient
Adult patients
Analysis
antiviral efficacy
assigned
Bacterial infection
Belgium
block
Breastfeeding
Chronic kidney disease
clinical
clinical benefit
Clinical efficacy
clinical evidence
Clinical research
clinical status
Combination
Commission
computer-generated
conducted
control group
Controlled trial
COVID-19
criteria
death
development
discharged
distribution
elevated
elevated liver enzymes
eligible
enrolled
Europe
European
evaluate
evidence of
exclusion criteria
extracorporeal membrane oxygenation
followed by
France
French
group
Health care
hepatorenal syndrome
high flow oxygen devices
hospital
hospitalised
Hydroxychloroquine
Inclusion
indication
Innovation
intention-to-treat population
interferon
interferon beta
Interferon beta-1a
intravenous
intravenous infusion
Invasive mechanical ventilation
investigators
Kidney disease
laboratory-confirmed SARS-CoV-2 infection
limitation
liver enzymes
Lopinavir
Lopinavir-ritonavir
Luxembourg
material
Ministry of Health
modified intention-to-treat
multicentre
no significant difference
non-invasive ventilation
not significant
Occurrence
Odds ratio
once daily
one health
Open-label
Ordinal Scale
oxygen
oxygen supplementation
oxygen support
participant
Patient
Phase 3
Pneumonia
Portugal
Pregnancy
Primary outcome
random assignment
randomisation
randomised
Randomly
receive
Regional
Registered
Remdesivir
required
requiring supplemental oxygen
respiratory distress
ribavirin
Ritonavir
Safety
SARS-CoV-2
SARS-COV-2 infection
Secondary outcomes
Serious Adverse Event
Serious Adverse Events
seven-point ordinal scale
Severity of disease
Sponsor
Standard of care
stratified
supplemental oxygen
Support
symptomatic
syndrome
the WHO
translation
Treatment
treatment group
treatment groups
Trial
Tumor
union
ventilator
were excluded
WHO ordinal scale
with COVID-19
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/S1473-3099(21)00485-0 PMC 바로가기 [Article Type] Clinical Trial